Category Archives: News

Although validated patient-reported outcome measurements (PRO) can categorize patients with inflammatory bowel disease (IBD) into remission or active disease, patients may have different definitions of remission. Patients may assume a new normal with a… Continue reading →

Ulcerative colitis (UC) is associated with liver disorders due to various etiologies. Some are diagnosed on basis of deranged liver function tests, imaging, and/or histology. Data on fibroscan in UC is scarce. A previous study had shown no significant … Continue reading →

Risk stratification of patients with Inflammatory Bowel Disease (IBD) is integral for patient management according to care pathways and IBD guidelines. We examined explicit IBD risk stratification and the extent of its influence on patient management i… Continue reading →

Poor sleep occurs in 75% of people with IBD and is prospectively associated with increased risk for disease flare, hospitalization, surgery, and reduced quality of life. While IBD providers know the link between poor sleep and IBD, few are adequately a… Continue reading →

Mucosal repair is the goal of medical therapy in IBD. Prospective inception cohort pediatric studies suggest that suppression of mitochondrial genes lead to unfavorable clinical outcomes in ulcerative colitis (UC) and Crohn’s disease (CD). We posit tha… Continue reading →

Inadequate response, loss of response, or intolerance to a first-line biologic typically requires patients with ulcerative colitis (UC) to switch treatment to a second-line biologic therapy. However, the clinical outcomes of patients receiving differen… Continue reading →

Disease-related stigmatization is present in patients with IBD and includes internalization of discriminatory attitudes or behaviors. Prior studies show IBD-related stigma is associated with worse clinical outcomes. However, this has not been well-stud… Continue reading →

In patients with ulcerative colitis (UC), Escherichia coli Nissle 1917 (EcN) is equivalent to mesalazine for preventing disease relapse; however, data regarding the ability of EcN to increase health-related quality of life or induce remission, compared… Continue reading →

Treatment with biologic medications for patients with inflammatory bowel disease (IBD) requires authorization by insurers. Insurance authorization denials are often a major obstacle in many clinical scenarios to use biologics, including specific denial… Continue reading →

IBD affects 3 million individuals in the US alone but the prevalence is expanding globally. The economic burden of IBD in the US is high, with estimates indicating the combined IBD population in the US is expected to incur a lifetime total cost of over… Continue reading →